Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The valsartan heart failure trial (Val-HEFT)

Roberto Latini, Serge Masson, Inder Anand, Dianne Judd, Aldo P. Maggioni, Yann Tong Chiang, Maurizio Bevilacqua, Monica Salio, Paola Cardano, Peter H J M Dunselman, Nicolaas J. Holwerda, Gianni Tognoni, Jay N. Cohn

Research output: Contribution to journalArticlepeer-review

Abstract

Background - Brain natriuretic peptide (BNP) and norepinephrine (NE) are strongly related to severity of and are independent predictors of outcome in heart failure. The long-term effects of angiotensin receptor blockers on BNP and NE in heart failure patients are not known. Methods and Results - Both BNP and NE were measured in 4284 patients randomized to valsartan or placebo in the Valsartan Heart Failure Trial (Val-HeFT) at baseline and 4, 12, and 24 months after randomization. The effects of valsartan were tested by ANCOVA, controlling for baseline values and concomitant ACE inhibitors and/or β-blockers. BNP and NE concentrations were similar at baseline in the 2 groups and were decreased by valsartan starting at 4 months and up to 24 months. BNP increased over time in the placebo group. At the end point, least-squares mean (±SEM) BNP increased from baseline by 23±5 pg/mL in the placebo group (n=1979) but decreased by 21±5 pg/mL (n=1940) in the valsartan group (P

Original languageEnglish
Pages (from-to)2454-2458
Number of pages5
JournalCirculation
Volume106
Issue number19
DOIs
Publication statusPublished - Nov 5 2002

Keywords

  • Angiotensin
  • Heart failure
  • Natriuretic peptides
  • Norepinephrine
  • Trials

ASJC Scopus subject areas

  • Physiology

Fingerprint Dive into the research topics of 'Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The valsartan heart failure trial (Val-HEFT)'. Together they form a unique fingerprint.

Cite this